11280 related articles for article (PubMed ID: 1322803)
1. Antitumor activity and cross-resistance of carmethizole hydrochloride in preclinical models in mice.
Waud WR; Plowman J; Harrison SD; Dykes DJ; Anderson WK; Griswold DP
Cancer Chemother Pharmacol; 1992; 30(4):261-6. PubMed ID: 1322803
[TBL] [Abstract][Full Text] [Related]
2. Schedule dependence, activity against natural metastases, and cross-resistance of pyrazine diazohydroxide (sodium salt, NSC 361456) in preclinical models in vivo.
Harrison SD; Plowman J; Dykes DJ; Waud WR; Griswold DP
Cancer Chemother Pharmacol; 1990; 25(6):425-9. PubMed ID: 2311170
[TBL] [Abstract][Full Text] [Related]
3. Design, synthesis, antineoplastic activity, and chemical properties of bis(carbamate) derivatives of 4,5-bis(hydroxymethyl)imidazole.
Anderson WK; Bhattacharjee D; Houston DM
J Med Chem; 1989 Jan; 32(1):119-27. PubMed ID: 2909723
[TBL] [Abstract][Full Text] [Related]
4. In vivo and in vitro evaluation of the alkylating agent carmethizole.
Elliott WL; Fry DW; Anderson WK; Nelson JM; Hook KE; Hawkins PA; Leopold WR
Cancer Res; 1991 Sep; 51(17):4581-7. PubMed ID: 1873802
[TBL] [Abstract][Full Text] [Related]
5. In vivo antitumor activity of S 16020-2, a new olivacine derivative.
Guilbaud N; Kraus-Berthier L; Saint-Dizier D; Rouillon MH; Jan M; Burbridge M; Visalli M; Bisagni E; Pierré A; Atassi G
Cancer Chemother Pharmacol; 1996; 38(6):513-21. PubMed ID: 8823492
[TBL] [Abstract][Full Text] [Related]
6. Cross-resistance of drug-resistant murine leukemias to deoxyspergualin (NSC 356894) in vivo.
Harrison SD; Brockman RW; Trader MW; Laster WR; Griswold DP
Invest New Drugs; 1987 Dec; 5(4):345-51. PubMed ID: 3436739
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of DMP 840: a novel bis-naphthalimide cytotoxic agent with human solid tumor xenograft selectivity.
McRipley RJ; Burns-Horwitz PE; Czerniak PM; Diamond RJ; Diamond MA; Miller JL; Page RJ; Dexter DL; Chen SF; Sun JH
Cancer Res; 1994 Jan; 54(1):159-64. PubMed ID: 8261436
[TBL] [Abstract][Full Text] [Related]
8. Preclinical antitumor activity of bizelesin in mice.
Carter CA; Waud WR; Li LH; DeKoning TF; McGovren JP; Plowman J
Clin Cancer Res; 1996 Jul; 2(7):1143-9. PubMed ID: 9816280
[TBL] [Abstract][Full Text] [Related]
9. Antitumor activity of TZT-1027, a novel dolastatin 10 derivative.
Kobayashi M; Natsume T; Tamaoki S; Watanabe J; Asano H; Mikami T; Miyasaka K; Miyazaki K; Gondo M; Sakakibara K; Tsukagoshi S
Jpn J Cancer Res; 1997 Mar; 88(3):316-27. PubMed ID: 9140117
[TBL] [Abstract][Full Text] [Related]
10. The effectiveness of the anthracycline analog 4'-epidoxorubicin in the treatment of experimental tumors: a review.
Goldin A; Venditti JM; Geran R
Invest New Drugs; 1985; 3(1):3-21. PubMed ID: 3886588
[TBL] [Abstract][Full Text] [Related]
11. Antitumor drug cross-resistance in vivo in a cisplatin-resistant murine P388 leukemia.
Waud WR; Harrison SD; Gilbert KS; Laster WR; Griswold DP
Cancer Chemother Pharmacol; 1991; 27(6):456-63. PubMed ID: 1849465
[TBL] [Abstract][Full Text] [Related]
12. Preclinical antitumor activity of penclomedine in mice: cross-resistance, schedule dependence, and oral activity against tumor xenografts in brain.
Harrison SD; Plowman J; Dykes DJ; Waud WR; Griswold DP
Cancer Res; 1991 Apr; 51(8):1979-83. PubMed ID: 2009516
[TBL] [Abstract][Full Text] [Related]
13. Activity of a novel anthracenyl bishydrazone, 9,10-anthracenedicarboxyaldehyde Bis[(4,5-dihydro-1H-imidazol-2-yl)hydrazone] dihydrochloride, against experimental tumors in mice.
Citarella RV; Wallace RE; Murdock KC; Angier RB; Durr FE; Forbes M
Cancer Res; 1982 Feb; 42(2):440-4. PubMed ID: 7055799
[TBL] [Abstract][Full Text] [Related]
14. In vivo tumor growth inhibition produced by a novel sulfonamide, E7010, against rodent and human tumors.
Koyanagi N; Nagasu T; Fujita F; Watanabe T; Tsukahara K; Funahashi Y; Fujita M; Taguchi T; Yoshino H; Kitoh K
Cancer Res; 1994 Apr; 54(7):1702-6. PubMed ID: 8137285
[TBL] [Abstract][Full Text] [Related]
15. Antitumor activity of cis-malonato[(4R,5R)-4,5-bis(aminomethyl)-2- isopropyl-1,3-dioxolane]platinum(II), a new platinum analogue, as an anticancer agent.
Kim DK; Kim HT; Cho YB; Tai JH; Ahn JS; Kim TS; Kim KH; Hong WS
Cancer Chemother Pharmacol; 1995; 35(5):441-5. PubMed ID: 7850928
[TBL] [Abstract][Full Text] [Related]
16. Preclinical pharmacologic studies of the new antitumor agent carmethizole (NSC-602668) in the mouse and beagle dog.
Brodfuehrer JI; Wilke TJ; Kinder DH; Powis G
Cancer Chemother Pharmacol; 1989; 24(5):277-83. PubMed ID: 2758557
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of antitumor activity of 1-beta-D-arabinofuranosyl-2-amino-1,4(2H)-4-iminopyrimidine in murine tumors.
Furusawa S; Mian AM
Cancer Treat Rep; 1987 May; 71(5):441-6. PubMed ID: 3567967
[TBL] [Abstract][Full Text] [Related]
18. Antitumor activity of intoplicine (RP 60475, NSC 645008), a new benzo-pyrido-indole: evaluation against solid tumors and leukemias in mice.
Bissery MC; Nguyen CH; Bisagni E; Vrignaud P; Lavelle F
Invest New Drugs; 1993 Nov; 11(4):263-77. PubMed ID: 8157469
[TBL] [Abstract][Full Text] [Related]
19. Synthesis, chemical reactivity, and antitumor evaluation of congeners of carmethizole hydrochloride, an experimental "acylated vinylogous carbinolamine" tumor inhibitor.
Jarosinski MA; Reddy PS; Anderson WK
J Med Chem; 1993 Nov; 36(23):3618-27. PubMed ID: 8246230
[TBL] [Abstract][Full Text] [Related]
20. Antitumor activity of a new fluoropyrimidine derivative, 5'-deoxy-5-fluorouridine, against murine and human experimental tumors.
Fujimoto S; Wang Y; Inoue K; Ogawa M
Jpn J Cancer Res; 1985 Jul; 76(7):644-50. PubMed ID: 3161854
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]